An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice

被引:55
作者
Remaud, G [1 ]
Boisdron-Celle, M [1 ]
Harneline, C [1 ]
Morel, A [1 ]
Gamelin, E [1 ]
机构
[1] INSERM, Dept Med Oncol, U564, Anticanc Ctr Paul Papin, F-49933 Angers, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 823卷 / 02期
关键词
fluoropyrimidines; uracil; dihydrouracil; HPLC;
D O I
10.1016/j.jchromb.2005.05.044
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An accurate and improved HPLC method was set up to measure both dihydrouracil (UH2) and uracil (U) in plasma, and to assess their ratio. Analytes retention time, separation and peak purity were greatly optimized with a Hypercarb column and a diode array detector. U and UH2 limits of quantification were 1.25 and 0.625 ng/mL. U and UH2 within-day precisions were 0.9-2.3% and 0.7-5.6%. Between-day precisions were 1.3-5.3% and 1.3-7.1%. Accuracy was 0.1-6.1%. UH2/U ratio between-day variability was low, but ratio decreased from 02:00 p.m. This method is now used in practice to detect patients at risk of fluoropyrimidine toxicity and to individually adapt the dosage. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:98 / 107
页数:10
相关论文
共 23 条
[1]   Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography [J].
Ackland, SP ;
Garg, MB ;
Dunstan, RH .
ANALYTICAL BIOCHEMISTRY, 1997, 246 (01) :79-85
[2]   ELEVATED URINE, BLOOD AND CEREBROSPINAL-FLUID LEVELS OF URACIL AND THYMINE IN A CHILD WITH DIHYDROTHYMINE DEHYDROGENASE-DEFICIENCY [J].
BAKKEREN, JAJM ;
DEABREU, RA ;
SENGERS, RCA ;
GABREELS, FJM ;
MAAS, JM ;
RENIER, WO .
CLINICA CHIMICA ACTA, 1984, 140 (03) :247-256
[3]   DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY LEADING TO THYMINE-URACILURIA - AN INBORN ERROR OF PYRIMIDINE METABOLISM [J].
BERGER, R ;
STOKERDEVRIES, SA ;
WADMAN, SK ;
DURAN, M ;
BEEMER, FA ;
DEBREE, PK ;
WEITSBINNERTS, JJ ;
PENDERS, TJ ;
VANDERWOUDE, JK .
CLINICA CHIMICA ACTA, 1984, 141 (2-3) :227-234
[4]   Known variant DPYD alleles do not explain DPD deficiency in cancer patients [J].
Collie-Duguid, ESR ;
Etienne, MC ;
Milano, G ;
McLeod, HL .
PHARMACOGENETICS, 2000, 10 (03) :217-223
[5]   POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS [J].
ETIENNE, MC ;
LAGRANGE, JL ;
DASSONVILLE, O ;
FLEMING, R ;
THYSS, A ;
RENEE, N ;
SCHNEIDER, M ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2248-2253
[6]  
FLEMING RA, 1993, EUR J CANCER, V29A, P740
[7]   Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer:: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage [J].
Gamelin, E ;
Boissdron-Celle, M ;
Guérin-Meyer, V ;
Delva, R ;
Lortholary, A ;
Genevieve, F ;
Larra, F ;
Ifrah, N ;
Robert, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1105-1110
[8]   A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites [J].
Gamelin, E ;
BoisdronCelle, M ;
Larra, F ;
Robert, J .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 1997, 20 (19) :3155-3172
[9]   Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin:: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients [J].
Gamelin, É ;
Boisdron-Celle, M ;
Delva, R ;
Regimbeau, C ;
Cailleux, PE ;
Alleaume, C ;
Maillet, ML ;
Goudier, MJ ;
Sire, M ;
Person-Joly, MC ;
Maigre, M ;
Maillart, P ;
Fety, R ;
Burtin, P ;
Lortholary, A ;
Dumesnil, Y ;
Picon, L ;
Geslin, J ;
Gesta, P ;
Danquechin-Dorval, E ;
Larra, F ;
Robert, J .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1470-1478
[10]  
Gamelin EC, 1996, CANCER, V77, P441, DOI 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO